A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Recruiting in Palo Alto (17 mi)

+18 other locations

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Pfizer

No Placebo Group

Trial Summary

What is the purpose of this trial?

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Eligibility Criteria

Inclusion Criteria

Adequate bone marrow, kidney and liver function

Histological or cytological diagnosis of prostate cancer

Hormone sensitive relapsing prostate cancer after definitive local therapy (biochemical relapse) OR Failed prior therapy with a novel hormone (e.g. enzalutamide, abiraterone) with documented progressive disease (post-novel hormone therapy CRPC)